Literature DB >> 12034254

Effectiveness of aggressive prophylatic and preemptive therapies targeted against cytomegaloviral and Epstein-Barr viral disease after human intestinal transplantation.

D G Farmer1, S V McDiarmid, D Winston, H Yersiz, G Cortina, S Dry, A J Maxfield, B Vandenbogaart, M Correa, A Kroeber, S Geevarghese, R W Busuttil.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12034254     DOI： 10.1016/s0041-1345(02)02710-0

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  4 in total

Review 1.  Theodore E. Woodward Award: development of novel, EBV-targeted therapies for EBV-positive tumors.

Authors:  Shannon Kenney
Journal:  Trans Am Clin Climatol Assoc       Date:  2006

Review 2.  Posttransplant lymphoproliferative disease: pathogenesis, monitoring, and therapy.

Authors:  Richard F Ambinder
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

3.  Incidence, timing, and significance of early hypogammaglobulinemia after intestinal transplantation.

Authors:  Douglas G Farmer; Omar M Kattan; Laura J Wozniak; Elizabeth Marcus; Susan Ponthieux; Villy Hwang; Ronald W Busuttil; Suzanne V McDiarmid; Robert S Venick
Journal:  Transplantation       Date:  2013-05-15       Impact factor: 4.939

4.  Small bowel transplant: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2003-04-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.